Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2006 2
2007 1
2008 5
2009 16
2010 62
2011 93
2012 107
2013 109
2014 133
2015 16
2016 12
2017 14
2018 16
2019 19
2020 42
2021 99
2022 92
2023 43
2024 1

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 20956938

778 results

Results by year

Filters applied: . Clear all
Page 1
Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL. Dunn EF, et al. Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18. Oncogene. 2011. PMID: 20956938 Free PMC article.
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC. Weickhardt AJ, et al. J Clin Oncol. 2012 May 1;30(13):1505-12. doi: 10.1200/JCO.2011.38.6599. Epub 2012 Mar 12. J Clin Oncol. 2012. PMID: 22412142 Clinical Trial.
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. Misale S, et al. Nature. 2012 Jun 28;486(7404):532-6. doi: 10.1038/nature11156. Nature. 2012. PMID: 22722830 Free PMC article.
Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T. Chen P, et al. Theranostics. 2020 Apr 6;10(11):5107-5119. doi: 10.7150/thno.44705. eCollection 2020. Theranostics. 2020. PMID: 32308771 Free PMC article.
778 results